|
Recruiting
|
NCT05209074 -
Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
|
Phase 1 |
|
Recruiting
|
NCT04969731 -
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
|
Phase 3 |
|
Recruiting
|
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 |
|
Recruiting
|
NCT05048524 -
Peri-operative SLOG for Localized Pancreatic Cancer
|
Phase 2 |
|
Terminated
|
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 |
|
Completed
|
NCT03257150 -
A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer
|
N/A |
|
Terminated
|
NCT04400903 -
Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer
|
|
|
Active, not recruiting
|
NCT05462717 -
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
|
Phase 1 |
|
Active, not recruiting
|
NCT03267316 -
A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors
|
Phase 1/Phase 2 |
|
Recruiting
|
NCT04970056 -
Pancreatic Cancer Early Detection Consortium
|
|
|
Terminated
|
NCT04046887 -
Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)
|
Phase 1 |
|
Recruiting
|
NCT05964621 -
Venous Thromboembolism in Primary Pancreatic Tumour Resection
|
|
|
Active, not recruiting
|
NCT04827953 -
Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer
|
Phase 1/Phase 2 |
|
Recruiting
|
NCT04291651 -
UCSF PANC Cyst Registry
|
|
|
Recruiting
|
NCT05977322 -
A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.
|
Phase 1 |
|
Recruiting
|
NCT05692596 -
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
|
|
|
Active, not recruiting
|
NCT04853017 -
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
|
Phase 1 |
|
Active, not recruiting
|
NCT04862260 -
Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma
|
Early Phase 1 |
|
Completed
|
NCT02259114 -
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)
|
Phase 1 |
|
Recruiting
|
NCT04146298 -
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
|
Phase 1/Phase 2 |